Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyClover Health Aucatzyl Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentClover HealthPolicy 6731-A

    Standard Medicare Part B Management Aucatzyl

    Customize your policy alerts

    Sign up for clover_health Policy 6731-A alerts

    Get alerted when Policy 6731-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs Medicare Part B coverage and prior authorization for Aucatzyl in adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia or lymphoblastic lymphoma, subject to disease, treatment-history, CD19-expression, functional-status, and safety criteria.

    Policy Summary
    PayerClover Health
    PolicyStandard Medicare Part B Management Aucatzyl
    Policy CodePolicy 6731-A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionProvide chart notes or medical records demonstrating failure of previous lines of therapy upon request.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3 monthsAuthorization duration
    AdultsMinimum age population
    CD19+Required disease biomarker
    2Covered disease settings
    ECOG <3Functional-status requirement

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Eligibility and Coverage Requirements

    Adult Relapsed or Refractory B-cell Precursor ALL or Lymphoblastic Lymphoma

    Authorization for 3 months (one split-dose) may be granted for treatment of relapsed or refractory B-cell precursor ALL/LL when all of the following criteria are met:

    ALL of the following

    • The member has not received a previous treatment course of the requested medication or another CD19-directed chimeric antigen receptor (CAR-T) therapy, or any prior CD19-directed therapy other than blinatumomab.
    • The member meets ONE of the following disease criteria:

      • Philadelphia chromosome-negative disease

        • The member has primary refractory disease.
        • The member has a first relapse with remission of 12 months or less.
        • The member has relapsed or refractory disease after at least 2 previous lines of systemic therapy.
        • The member has relapsed or refractory disease after allogeneic stem cell transplant (allo-SCT).
      • Philadelphia chromosome-positive disease

        • The member meets ONE of the following:

          • The member has relapsed or refractory disease despite treatment with at least 2 different tyrosine kinase inhibitors (TKIs), such as bosutinib, dasatinib, imatinib, nilotinib, or ponatinib, or one line of second-generation TKI.
          • The member is intolerant to TKI therapy or TKI therapy is contraindicated.
    • The disease is CD19 positive.

    Coverage will not be provided for members with any of the following exclusions:

    - Age less than 18 years

    - Eastern Cooperative Oncology Group (ECOG) performance status greater than or equal to 3 (member is not ambulatory and not capable of all self-care, confined to bed or chair more than 50% of waking hours)

    - Inadequate and unstable kidney, liver, pulmonary, or cardiac function

    - Active hepatitis B, active hepatitis C, or any active uncontrolled infection

    - Active inflammatory disorder

    - History or presence of clinically relevant central nervous system (CNS) pathology

    - Active graft-versus-host disease

    Disease and Biomarker Status

    CD19
    Required statusCD19-positive disease is required for coverage.
    Required findingCD19-positive expression must be demonstrated on leukemic blasts.
    Acceptable testing sitesTesting or analysis may confirm CD19 expression on leukemic blasts in the bone marrow, peripheral blood, or cerebrospinal fluid.
    Philadelphia chromosome status
    Applicable disease statusThe member must have either Philadelphia chromosome-negative or Philadelphia chromosome-positive disease.
    Ph-negative pathwayDisease must be relapsed or refractory and meet at least one specified Ph-negative disease definition.

    Prior Treatment and Salvage Therapy

    Salvage Treatment — Philadelphia Chromosome-Negative Disease

    The member meets at least one of the following salvage-treatment criteria for Philadelphia chromosome-negative disease:

    Relapsed or refractory disease history: The member has primary refractory disease, first relapse with remission of 12 months or less, relapsed or refractory disease after at least 2 previous lines of systemic therapy, or relapsed or refractory disease after allogeneic stem cell transplant.

    Applies to the Philadelphia chromosome-negative pathway.

    Salvage Treatment — Philadelphia Chromosome-Positive Disease

    The member meets at least one of the following salvage-treatment criteria for Philadelphia chromosome-positive disease:

    Philadelphia chromosome-positive treatment history

    • TKI-resistant disease: The member has relapsed or refractory disease despite treatment with at least 2 different tyrosine kinase inhibitors or one line of a second-generation tyrosine kinase inhibitor.

    Covered Aucatzyl Uses

    RegimenIndicationCoverage
    Aucatzyl (obecabtagene autoleucel)Adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)Covered, subject to all policy criteria
    RegimenIndicationCoverage
    Aucatzyl (obecabtagene autoleucel)Lymphoblastic lymphomaCovered, compendial use subject to all policy criteria

    Authorization and Documentation Actions

    Prior Authorization

    Request authorization for one 3-month split-dose course

    Prior authorization may be granted for 3 months for one split-dose course when all coverage criteria are met, including qualifying relapsed or refractory B-cell precursor ALL or lymphoblastic lymphoma, no prohibited prior CD19-directed therapy, and CD19-positive disease.

    Documentation Required

    Document failure of previous therapy

    Upon request, provide chart notes or medical records demonstrating failure of previous lines of therapy.

    Documentation Required

    Confirm CD19 expression

    Upon request, provide testing or analysis confirming CD19 expression on leukemic blasts in the bone marrow, peripheral blood, or cerebrospinal fluid.

    Clinical Definitions

    ECOG performance status 3 or greater
    Coverage exclusion thresholdECOG performance status greater than or equal to 3 is excluded from coverage.
    Ambulation and self-careThe member is not ambulatory and is not capable of all self-care.
    Time confined to bed or chairThe member is confined to bed or chair for more than 50% of waking hours.
    Relapsed or refractory Ph-negative disease
    Qualifying pathwayPh-negative disease must be relapsed or refractory and meet at least one of the listed categories.
    Primary refractory diseaseThe member has primary refractory disease.

    Therapy and Policy Background

    Aucatzyl (obecabtagene autoleucel) is a CD19-directed chimeric antigen receptor T-cell therapy. This policy addresses its FDA-approved use in adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia and its compendial use in lymphoblastic lymphoma, subject to the policy’s coverage criteria, including qualifying disease history and CD19-positive disease. Coverage is administered under Medicare Part B CAR-T coverage conditions.

    Policy Summary
    PayerClover Health
    PolicyStandard Medicare Part B Management Aucatzyl
    Policy CodePolicy 6731-A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionProvide chart notes or medical records demonstrating failure of previous lines of therapy upon request.
    SourceLink
    On This Page
    Eligibility and Coverage RequirementsDisease and Biomarker StatusPrior Treatment and Salvage TherapyCovered Aucatzyl UsesAuthorization and Documentation ActionsClinical DefinitionsTherapy and Policy Background
    Ph-positive pathway: treatment resistanceRelapsed or refractory disease despite treatment with at least 2 different tyrosine kinase inhibitors (TKIs) or one line of a second-generation TKI qualifies.
    Ph-positive pathway: intolerance or contraindicationIntolerance to TKI therapy or a contraindication to TKI therapy qualifies.
    >= 2 different TKIs or 1 second-generation TKI

    Examples include bosutinib, dasatinib, imatinib, nilotinib, and ponatinib.

  1. TKI intolerance or contraindication: The member is intolerant to TKI therapy or TKI therapy is contraindicated.
  2. Denial Risk

    Screen for exclusion conditions

    Coverage will not be provided when any listed exclusion is present. Verify the member meets the age, functional-status, organ-function, and active-condition requirements before submitting the request.

    • Age less than 18 years
    • ECOG performance status greater than or equal to 3
    • Inadequate and unstable kidney, liver, pulmonary, or cardiac function
    • Active hepatitis B, active hepatitis C, or any active uncontrolled infection
    • Active inflammatory disorder
    • History or presence of clinically relevant central nervous system pathology
    • Active graft-versus-host disease
    Denial Risk

    Verify eligibility and treatment history

    Authorization may be denied if the member has previously received Aucatzyl or another CD19-directed CAR-T therapy, has received prior CD19-directed therapy other than blinatumomab, does not meet the specified relapsed or refractory disease criteria, or does not have CD19-positive disease.

    • Confirm no previous treatment course of Aucatzyl.
    • Confirm no prior CD19-directed CAR-T therapy.
    • Confirm no prior CD19-directed therapy other than blinatumomab.
    • Document qualifying relapsed or refractory disease.
    • Confirm CD19-positive disease.
    Early first relapse
    The member has a first relapse with remission of 12 months or less.
    After multiple systemic therapiesThe member has relapsed or refractory disease after at least 2 previous lines of systemic therapy.
    After allogeneic stem cell transplantThe member has relapsed or refractory disease after allogeneic stem cell transplant (allo-SCT).